摘要
肺癌是目前最常见的恶性肿瘤之一,其发病率有逐年增高的趋势,且患者的预后及生存期很差。贝伐单抗于2004-02-26获得美国食品药品监督管理局(FDA)批准,是美国第一个批准上市的抑制肿瘤血管生成的药物,在肺癌的药物治疗中占据重要地位。目前贝伐单抗在肺癌中的研究多从1或2个角度来论述,难以让读者清楚贝伐单抗与肺癌的关系。本文主要从血管内皮生长因子在肿瘤发病机制中的作用、贝伐单抗治疗肺癌的机制、所检测的生物标志物、分期研究、耐药机制及毒副作用等角度较为全面地阐述贝伐单抗在肺癌中的研究进展。
Lung cancer is one of the most common malignant tumor at present,its morbidity tends to increase year by year,and the prognosis and survival of the patients is poor. Bevacizumab,the first anti- tumor angiogenesis drug which was approved on sale by FDA on 26 February 2004, is an important drug for lung cancer treatment. At present, the studies on Bevacizumab in treatment of lung cancer mainly focus on one or two perspectives, thus readers can not fully understand the relationship between Bevacizumab and lung cancer. The research progress of Bevacizumab in treatment of lung cancer is comprehensively discussed in this paper from the perspective of the role of vascular endothelial growth factor in the pathogenesis of cancer,the mechanism of Bevacizumab in treatment of lung cancer,therelated biomarkers,studies on staging,mechanism of drug resistance and adverse effects of Bevacizumab in treatment of lung cancer.
出处
《中国全科医学》
CAS
CSCD
北大核心
2015年第9期1002-1005,共4页
Chinese General Practice
基金
国家自然科学基金青年项目(81302934)
浙江省科技厅钱江人才计划(2012R10063)
关键词
肺肿瘤
贝伐单抗
受体
血管内皮生长因子
生物学标记
药理学
抗药性
肿瘤
药物毒性
Lung neoplasms
Bevacizumab
Receptors
vascular endothelial growth factors
Biomarkers
pharmacological
Drug resistance
neoplasms
Drug toxicity
